Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

In the latest session, Travere Therapeutics Inc (NASDAQ: TVTX) closed at $17.28 up 2.01% from its previous closing price of $16.94. In other words, the price has increased by $2.01 from its previous closing price. On the day, 1.14 million shares were traded. TVTX stock price reached its highest trading level at $17.62 during the session, while it also had its lowest trading level at $16.965.

Ratios:

For a deeper understanding of Travere Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 12.20 whereas as Long-Term Debt/Eq ratio is at 9.93.

On June 11, 2025, Citigroup reiterated its Buy rating and also upped its target price recommendation from $35 to $32.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 01 ’25 when Inrig Jula sold 815 shares for $14.65 per share. The transaction valued at 11,940 led to the insider holds 88,787 shares of the business.

Cline Christopher R. sold 1,784 shares of TVTX for $37,553 on May 05 ’25. The CHIEF FINANCIAL OFFICER now owns 93,126 shares after completing the transaction at $21.05 per share. On May 05 ’25, another insider, Dube Eric M, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 18,924 shares for $21.05 each. As a result, the insider received 398,350 and left with 419,173 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 1540316928 and an Enterprise Value of 1620352256. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.61 while its Price-to-Book (P/B) ratio in mrq is 47.02. Its current Enterprise Value per Revenue stands at 4.853 whereas that against EBITDA is -13.443.

Stock Price History:

The Beta on a monthly basis for TVTX is 0.78, which has changed by 0.95475113 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, TVTX has reached a high of $25.29, while it has fallen to a 52-week low of $8.31. The 50-Day Moving Average of the stock is 11.37%, while the 200-Day Moving Average is calculated to be -3.88%.

Shares Statistics:

For the past three months, TVTX has traded an average of 1.58M shares per day and 1557710 over the past ten days. A total of 89.10M shares are outstanding, with a floating share count of 87.77M. Insiders hold about 1.54% of the company’s shares, while institutions hold 119.78% stake in the company. Shares short for TVTX as of 1752537600 were 12859589 with a Short Ratio of 8.16, compared to 1749772800 on 10329311. Therefore, it implies a Short% of Shares Outstanding of 12859589 and a Short% of Float of 14.580000000000002.

Earnings Estimates

At present, 6.0 analysts are actively evaluating the performance of Travere Therapeutics Inc (TVTX) in the stock market.The consensus estimate for the next quarter is $0.06, with high estimates of $0.29 and low estimates of -$0.06.

Analysts are recommending an EPS of between $0.08 and -$0.19 for the fiscal current year, implying an average EPS of -$0.07. EPS for the following year is $1.25, with 8.0 analysts recommending between $2.1 and $0.09.

Revenue Estimates

A total of 12 analysts believe the company’s revenue will be $107.19M this quarter.It ranges from a high estimate of $116.01M to a low estimate of $99.5M. As of the current estimate, Travere Therapeutics Inc’s year-ago sales were $62.9MFor the next quarter, 12 analysts are estimating revenue of $120.05M. There is a high estimate of $151.1M for the next quarter, whereas the lowest estimate is $105.2M.

A total of 13 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $458.5M, while the lowest revenue estimate was $398.68M, resulting in an average revenue estimate of $420.5M. In the same quarter a year ago, actual revenue was $233.18MBased on 14 analysts’ estimates, the company’s revenue will be $588.21M in the next fiscal year. The high estimate is $795.9M and the low estimate is $468.83M.